Different agonists that trigger innate receptors and sensors such as TLR, STING, RIG-1 and NLR are currently being developed and some, such as STING agonists, have been considered in clinical trials as ICI adjuvants for advanced melanoma and other solid tumors (Hu and Li, 2020); the activation of these receptors is intended to mimic the immune response against viruses, that ultimately trigger cytokines and chemokines that will break the suppressive TME and allow the infiltration of immune cells inside tumors (Clavijo-Salomon et al., 2017). Here, STING1 is linked to melanoma.